Navigation Links
Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:5/31/2008

reatment of recurrent glioblastoma multiforme (GBM)." Sunday, June 1, 2008 2:00 PM - 6:00 PM CDT.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that dose-limiting toxicities may be experienced in future stages of the trial which will use higher doses of Cotara. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
4. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
5. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
6. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
10. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... Minn. , May 23, 2013  MGC Diagnostics ... a global medical technology company, today scheduled a conference ... quarter of fiscal year 2013, ended April 30, 2013. ... Thursday, May 30, 2013. The Company will report financial ... after the markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... The SCOOTER Store today announced a major milestone, saying it has ... power wheelchair to Earvin Thompson of Houston, Texas . ... leading provider of power mobility equipment, will enjoy more freedom and independence ... , ...
... GRONINGEN, The Netherlands , June 22, 2010 ... announced this week that in collaboration,with the University ... for the treatment of inhalation anthrax. In a rabbit ... time to treatment (48h post,infection) with a combination of ...
Cached Medicine Technology:The SCOOTER Store Marks Half-Millionth Life Changed 2The SCOOTER Store Marks Half-Millionth Life Changed 3The SCOOTER Store Marks Half-Millionth Life Changed 4Survival Rate Up to 100% for Late Stage Treatment of Anthrax Infections 2
(Date:5/24/2013)... -- Drugs commonly used to treat glaucoma may cause ... with vision, according to a new study. The ... to reduce eye pressure, have already been shown to ... the researchers said, suggesting that the new findings could ... should be conservative when prescribing these drugs, the researchers ...
(Date:5/24/2013)... Lake City, Utah (PRWEB) May 24, 2013 ... 2.0 , with exciting new enhancements for instructors and ... students stay more focused through personalize learning plan templates, ... new AnatomyOne release provides 500 new assessment questions, 5,000 ... and review notes. , AnatomyOne 2.0 is ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV and ... compare the features and services offered by leading ... the rankings of the best rural Internet ... on their website. , BestSatelliteProviders.com – ... Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers were ...
(Date:5/24/2013)... to the National Institutes of Health, Stevens Johnson Syndrome (SJS) ... the skin and mucous membranes. SJS occurs most commonly ... (i). In the early stages SJS presents flu-like symptoms, ... it affects the mucous membranes such as the eyes, mouth ... eye causes conjunctivitis (pink eye). Inflammation of the mouth ...
(Date:5/24/2013)... News) -- The number of U.S. patients admitted ... in an emergency room has increased by nearly ... study, conducted by researchers at the George Washington ... in Washington, D.C., found that patients wait five ... being admitted to the ICU. The researchers said ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2
... The Diversified Agency Services (DAS),unit of Omnicom ... position of,Executive Vice President and Director of ... will direct the client-centric and,brand-centric teams within ... resource of specialist agencies that support,the strategic ...
... is ,good news, for postmenopausal women taking anastrozole ... to previous study results, the cancer prevention drug ... cognitive performance, a new study found. , ... tamoxifen in preventing breast cancer recurrence in postmenopausal ...
... WINSTON-SALEM, N.C. Scientists at Wake Forest University School ... cancer gene called HNF1B have found a second independent ... increasing the number of genetic variants that may ... comparing the newly-discovered site with a previously discovered site ...
... , The guidelines are developed through a rigorous ... the field and a review committee of 21 international ... the first time both acute and chronic heart failure. ... patients with acute heart failure often develop chronic problems ...
... largest multi-institutional study to date examining the impact of ... individuals with suspected recurrent colorectal cancer, researchers found that ... patients, according to an article in the September issue ... The study was conducted at four sites throughout Australia ...
... Dr. Charmaine Yoest,President and CEO of Americans United ... that the daughter of McCain running mate,Sarah Palin is ... know this situation is not the ideal,Sarah Palin wished ... life,s,challenges is the true testament to our character. The ...
Cached Medicine News:Health News:Sharon Callahan Joins Diversified Agency Services Unit of Omnicom Group 2Health News:Breast Cancer Drug Not Tied to Cognitive Decline: Study 2Health News:Scientists find second site for prostate cancer gene 2Health News:PET scans lead to treatment changes in majority of colorectal cancer patients 2
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
This ENDOLOOP suture has a suture type - 0 Coated VICRYL and a 1.5 inch diameter....
... bring modern Data Management capabilities to the ... wide range of settings and definable options, ... the operator for identification, lot numbers, quality ... This data can then be transmitted to ...
Bartels Clostridium difficile Toxin A Enzyme Immunoassay (EIA) is intended for the qualitative detection of Clostridium difficile Toxin A in human faecal specimens as an aid in the diagnosis of Clost...
Medicine Products: